Konference: 2009 XXXIII. Brněnské onkologické dny a XXIII. Konference pro sestry a laboranty
Kategorie: Zhoubné nádory prsu
Téma: I. Experimentální onkologie
Číslo abstraktu: 028p
Autoři: RNDr. Radka Václavíková, Ph.D.; H. S. Nordgard; G.A. Alnaes; Ing. Ivona Hlavatá; prof. MUDr. Roman Kodet, CSc.; RNDr. Marcela Mrhalová, Ph.D.; MUDr. Václav Pecha; MUDr. Renata Koževnikovová; Ivana Julišová; MUDr. Dagmar Pohnětalová; MUDr. Markéta Trnková; V. N. Kristensen; MUDr. Ivan Gut; RNDr. Pavel Souček, CSc.
Background
Cellular multidrug resistance (MDR) to anticancer drugs remains one
of the primary causes of suboptimal outcomes in cancer therapy.
ATP-binding cassette (ABC) transporters belong to a family of
transporter proteins that contribute to drug resistance via
ATP-dependent drug efflux pumps. The aim of this study was to
assess the role and clinical impact of ABCB1 and other ABC
transporter genes in development of breast cancer MDR.
Material and Methods
Expression profile of ABC transporter genes (ABCB1, ABCC1, ABCC2
and ABCG2) was evaluated in 90 breast cancer patients. Gene
expression was quantified in samples from tumor and non-tumor
breast tissues by real-time PCR. In addition, seven ABCB1
polymorphisms (SNPs) were analyzed using Nanogen electronic
microarrays and compared with High Resolution Melting Analysis.
Determination of associations between: 1/ expression of ABC
transporters, 2/ genetic variability and 3/ haplotype pattern of
ABCB1 on one side and clinico-pathological features including
survival of patients on the other side was performed.
Results
ABC transporters were expressed in majority of cases. Striking
inter-individual variability in their expression was found. ABCB1
was down-regulated in 79.5% of all tumors, while opposite, i.e.
up-regulation was observed for ABCC1 and ABCC2 expression. Similar
expression profiles were found in patients treated by neoadjuvant
and adjuvant chemotherapy. Patients with high ABCB1 expression
treated with P-gp substrates anthracyclineor taxane-containing
regimens had significantly shorter disease-free survival than those
treated by other regimens (P = 0.031). In genetic variation
studies, high frequencies of variant alleles in ABCB1 exon12
(C1236T, qT=38.3), exon21 (G2677T/A, qT=40.0) and exon26 (C3435T,
qT=54.0) were observed. Individuals with variant alleles in exons12
and 26 had significantly lower ABCB1 expression in their tumors
than patients with normal genotype. These two SNPs also correlated
with estrogen receptor status of patients (P=0.011 and P=0.051
respectively).
Conclusions
ABCB1 SNPs may affect function of protein by influencing the
expression level and modify breast cancer prognosis. Especially,
SNPs in exons 12 and 26 influenced ABCB1 expression and seem to be
good candidates for cancer validation studies. The observed
association between ABCB1 SNPs and estrogen receptor status of
patients warrants further research based on extended haplotype
analysis. Moreover, expression of ABCB1 in tumor tissue may be
considered as factor increasing the risk of failure of
anthracycline or taxane-based chemotherapy.
This work was supported by grants IGA 9426-3 and GACR
305/07/P347.
Datum přednesení příspěvku: 16. 4. 2009